



AUSTRALIA
Biotech
Invest 2016

Connecting Capital with Innovation

www.australiabiotechinvest.com.au

26 - 27
October
2016

Host Industry Body Host State Partner Major Partner

AusBiotech
AUSTRALIA'S BIOTECHNOLOGY ORGANISATION

MELBOURNE
Victoria
Australia

100^{cs}
Just getting started

Melbourne Convention
Centre, Victoria, Australia

Bionomics Company Profile

Bionomics is a clinical stage biopharmaceutical company leveraging its proprietary technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer. Bionomics has strategic partnerships with Merck & Co., Inc. in pain and cognition.